In addition to the Berlin site, two factories were also located in Russia (Moscow and Wydriza (Idritsa)) with over 1,000 workers and a plant in Great Britain.

In 1922, the management acquired the majority of shares in the chemical factory Chemischen Fabrik auf Actien (formerly E. Schering) from the Upper Silesian Oberschlesische Kokswerke und Chemische Fabriken [de].

[3] After the end of the Second World War, the Adlershof factory of Schering AG was located in the Soviet occupation zone and thus in the later German Democratic Republic; this part became the Berlin-Chemie pharmaceutical company.

[5][6] In 2003, Simon Rozenkier filed a lawsuit against Schering and Bayer concerning the horrific medical "experiments" the companies participated in during the Nazi era.

[7] [8] "If there was ever an example of why I titled the book about my Holocaust restitution negotiations in the Clinton administration “Imperfect Justice,” Stuart Eisenstadt wrote, "it is the case of Simon Rozenkier.

Writing in Forward, lawyer Stuart Eizenstat wrote: "During the allocation process it became painfully evident that we simply did not have enough money to achieve anything like full justice for all of the victims".

[10] In March 2006, Merck KGaA announced a €14.6bn bid for Schering, which by 2006 had annual gross revenue of around €5 billion[11] and employed about 26,000 people in 140 subsidiaries worldwide.